中国卒中杂志 ›› 2023, Vol. 18 ›› Issue (01): 17-41.DOI: 10.3969/j.issn.1673-5765.2023.01.002
王伊龙, 陈玮琪, 叶瑾怡, 周梦圆, 江凌玲, 刘东, 邱宝山, 高颖, 赵一龙, 王赞, 李鹏飞
收稿日期:
2023-01-10
出版日期:
2023-01-20
发布日期:
2023-01-20
通讯作者:
王伊龙 yilong528@gmail.com
Received:
2023-01-10
Online:
2023-01-20
Published:
2023-01-20
王伊龙, 陈玮琪, 叶瑾怡, 周梦圆, 江凌玲, 刘东, 邱宝山, 高颖, 赵一龙, 王赞, 李鹏飞. 脑小血管病:回眸2022[J]. 中国卒中杂志, 2023, 18(01): 17-41.
WANG Yilong, CHEN Weiqi, YE Jinyi, ZHOU Mengyuan, JIANG Lingling, LIU Dong, QIU Baoshan, GAO Ying, ZHAO Yilong, WANG Zan, LI Pengfei . Highlights in Cerebral Small Vessel Disease in 2022[J]. Chinese Journal of Stroke, 2023, 18(01): 17-41.
[1] CHARIDIMOU A,PANTONI L,LOVE S. The concept of sporadic cerebral small vessel disease:a road map on key definitions and current concepts[J]. Int J Stroke,2016,11(1):6-18. [2] SMITH E E,MARKUS H S. New treatment approaches to modify the course of cerebral small vessel diseases[J]. Stroke,2020,51(1):38-46. [3] MARKUS H S,FLIER W M,SMITH E E,et al. Framework for clinical trials in cerebral small vessel disease(FINESSE):a review[J]. JAMA Neurol,2022,79(11):1187-1198. [4] CANNISTRARO R J,BADI M,EIDELMAN B H,et al. CNS small vessel disease:a clinical review[J]. Neurology,2019,92(24):1146-1156. [5] BERNBAUM M,MENON B K,FICK G,et al. Reduced blood flow in normal white matter predicts development of leukoaraiosis[J]. J Cereb Blood Flow Metab,2015,35(10):1610-1615. [6] VEEN P H,MULLER M,VINCKEN K L,et al. Longitudinal relationship between cerebral small-vessel disease and cerebral blood flow:the second manifestations of arterial disease-magnetic resonance study[J]. Stroke,2015,46(5):1233-1238. [7] TEICH A F,SAKURAI M,PATEL M,et al. PDE5 exists in human neurons and is a viable therapeutic target for neurologic disease[J]. J Alzheimers Dis,2016,52(1):295-302. [8] VASITA E,YASMEEN S,ANDOH J,et al. The cGMP-degrading enzyme phosphodiesterase-5(PDE5)in cerebral small arteries of older people[J]. J Neuropathol Exp Neurol,2019,78(2):191-194. [9] FORGUE S T,PATTERSON B E,BEDDING A W,et al. Tadalafil pharmacokinetics in healthy subjects[J]. Br J Clin Pharmacol,2006,61(3):280-288. [10] GARCIA-OSTA A,CUADRADO-TEJEDOR M,GARCIA-BARROSO C,et al. Phosphodiesterases as therapeutic targets for Alzheimer’s disease[J]. ACS Chem Neurosci,2012,3(11):832-844. [11] PAULS M M H,BINNIE L R,BENJAMIN P,et al. The PASTIS trial:testing tadalafil for possible use in vascular cognitive impairment[J]. Alzheimers Dement,2022,18(12):2393-2402. [12] PFLANZ C P,EGLE M S,O’BRIEN J T,et al. Association of blood pressure lowering intensity with white matter network integrity in patients with cerebral small vessel disease[J/OL]. Neurology,2022,99(17):e1945-e1953[2023-01-03]. https://doi.org/10.1212/wnl.0000000000201018. [13] UMEMOTO S,OGIHARA T,MATSUZAKI M,et al. Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability:post hoc analysis of the COPE trial[J]. Hypertens Res,2016,39(1):46-53. [14] GOLDSTEIN E D,WOLCOTT Z,GARG G,et al. Effect of antihypertensives by class on cerebral small vessel disease:a post hoc analysis of SPRINT-MIND[J]. Stroke,2022,53(8):2435-2440. [15] SHIN H K,SALOMONE S,AYATA C. Targeting cerebrovascular Rho-kinase in stroke[J]. Expert Opin Ther Targets,2008,12(12):1547-1564. [16] MATSUI T,AMANO M,YAMAMOTO T,et al. Rho-associated kinase,a novel serine/threonine kinase,as a putative target for small GTP binding protein Rho[J]. Embo J,1996,15(9):2208-2216. [17] AYKAN S A,XIE H Y,ZHENG Y,et al. Rho-kinase inhibition improves the outcome of focal subcortical white matter lesions[J]. Stroke,2022,53(7):2369-2376. [18] BENAVENTE O R,HART R G,MCCLURE L A,et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke[J]. N Engl J Med,2012,367(9):817-825. [19] KWOK C S,SHOAMANESH A,COPLEY H C,et al. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke:pooled analysis of randomized trials[J]. Stroke,2015,46(4):1014-1023. [20] SHINOHARA Y,KATAYAMA Y,UCHIYAMA S,et al. Cilostazol for prevention of secondary stroke(CSPS 2):an aspirin-controlled,double-blind,randomised non-inferiority trial[J]. Lancet Neurol,2010,9(10):959-968. [21] OYAMA N,YAGITA Y,KAWAMURA M,et al. Cilostazol,not aspirin,reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats[J]. Stroke,2011,42(9):2571-2577. [22] KIM B C,YOUN Y C,JEONG J H,et al. Cilostazol versus aspirin on white matter changes in cerebral small vessel disease:a randomized controlled trial[J]. Stroke,2022,53(3):698-709. [23] BLAIR G W,JANSSEN E,STRINGER M S,et al. Effects of cilostazol and isosorbide mononitrate on cerebral hemodynamics in the LACI-1 randomized controlled trial[J]. Stroke,2022,53(1):29-33. [24] GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories,1990-2019:a systematic analysis for the global burden of disease study 2019[J]. Lancet,2020,396(10258):1204-1222. [25] WASSENAAR T M,YAFFE K,VAN DER WERF Y D,et al. Associations between modifiable risk factors and white matter of the aging brain:insights from diffusion tensor imaging studies[J/OL]. Neurobiol Aging,2019,80:56-70[2023-01-03]. https://doi.org/10.1016/j.neurobiolaging.2019.04.006. [26] BERRY C,SIDIK N,PEREIRA A C,et al. Small-vessel disease in the heart and brain:current knowledge,unmet therapeutic need,and future directions[J/OL]. J Am Heart Assoc,2019,8(3):e011104[2023-01-03]. https://doi.org/10.1161/jaha.118.011104. [27] MEJIA-RENTERIA H,TRAVIESO A,MATÍAS-GUIU J A,et al. Coronary microvascular dysfunction is associated with impaired cognitive function:the cerebral-coronary connection study(C3 study)[J]. Eur Heart J,2023,44(2):113-125. [28] FERGUSON A C,THRIPPLETON S,HENSHALL D,et al. Frequency and phenotype associations of rare variants in 5 monogenic cerebral small vessel disease genes in 200,000 UK biobank participants[J/OL]. Neurol Genet,2022,8(5):e200015[2023-01-03]. https://doi.org/10.1212/nxg.0000000000200015. [29] MISHRA A,DUPLAÀ C,VOJINOVIC D,et al. Gene-mapping study of extremes of cerebral small vessel disease reveals TRIM47 as a strong candidate[J]. Brain,2022,145(6):1992-2007. [30] HARSHFIELD E L,SANDS C J,TULADHAR A M,et al. Metabolomic profiling in small vessel disease identifies multiple associations with disease severity[J]. Brain,2022,145(7):2461-2471. [31] PEROSA V,OLTMER J,MUNTING L P,et al. Perivascular space dilation is associated with vascular amyloid-β accumulation in the overlying cortex[J]. Acta Neuropathol,2022,143(3):331-348. [32] VELUW S J,BIESSELS G J,BOUVY W H,et al. Cerebral amyloid angiopathy severity is linked to dilation of juxtacortical perivascular spaces[J]. J Cereb Blood Flow Metab,2016,36(3):576-580. [33] MONTAGNE A,ZHAO Z,ZLOKOVIC B V. Alzheimer’s disease:a matter of blood-brain barrier dysfunction? [J]. J Exp Med,2017,214(11):3151-3169. [34] CUADRADO-GODIA E,DWIVEDI P,SHARMA S,et al. Cerebral small vessel disease:a review focusing on pathophysiology,biomarkers,and machine learning strategies[J]. J Stroke,2018,20(3):302-320. [35] KALARIA R N. Small vessel disease and Alzheimer’s dementia:pathological considerations[J/OL]. Cerebrovasc Dis,2002,13(Suppl 2):48-52[2023-01-03]. https://doi.org/10.1159/000049150. [36] CHENG X,HE P,YAO H L,et al. Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy[J]. Neurology,2014,82(19):1707-1715. [37] ROSSNER S,LANGE-DOHNA C,ZEITSCHEL U,et al. Alzheimer’s disease beta-secretase BACE1 is not a neuron-specific enzyme[J]. J Neurochem,2005,92(2):226-234. [38] BOURASSA P,TREMBLAY C,SCHNEIDER J A,et al. Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex:relation with cerebral amyloid angiopathy and Alzheimer’s disease[J]. Acta Neuropathol,2019,137(5):801-823. [39] ZHOU H Y,GAO F,YANG X L,et al. Endothelial BACE1 impairs cerebral small vessels via tight junctions and eNOS[J]. Circ Res,2022,130(9):1321-1341. [40] CAI M F,JACOB M A,VAN LOENEN M R,et al. Determinants and temporal dynamics of cerebral small vessel disease:14-year follow-up[J]. Stroke,2022,53(9):2789-2798. [41] VERBURGT E,JANSSEN E,JACOB M A,et al. Role of small acute hyperintense lesions in long-term progression of cerebral small vessel disease and clinical outcome:a 14-year follow-up study[J]. J Neurol Neurosurg Psychiatry,2023,94(2):144. [42] KUO C Y,TAI T M,LEE P L,et al. Improving individual brain age prediction using an ensemble deep learning framework[J/OL]. Frontiers in psychiatry,2021,12:626677[2023-01-03]. https://doi.org/10.3389/fpsyt.2021.626677. [43] WARDLAW J M,SMITH C,DICHGANS M. Small vessel disease:mechanisms and clinical implications[J]. Lancet Neurol,2019,18(7):684-696. [44] LEE P L,KUO C Y,WANG P N,et al. Regional rather than global brain age mediates cognitive function in cerebral small vessel disease[J/OL]. Brain Commun,2022,4(5):fcac233[2023-01-03]. https://doi.org/10.1093/braincomms/fcac233. [45] HABES M,POMPONIO R,SHOU H C,et al. The brain chart of aging:machine-learning analytics reveals links between brain aging,white matter disease,amyloid burden,and cognition in the iSTAGING consortium of 10,216 harmonized MR scane[J]. Alzheimers Dement,2021,17(1):89-102. [46] KATZMAN R,TERRY R,DETERESA R,et al. Clinical,pathological,and neurochemical changes in dementia:a subgroup with preserved mental status and numerous neocortical plaques[J]. Ann Neurol,1988,23(2):138-144. [47] SNOWDON D A,KEMPER S J,MORTIMER J A,et al. Linguistic ability in early life and cognitive function and Alzheimer’s disease in late life. Findings from the Nun study[J]. JAMA,1996,275(7):528-532. [48] DEJONG N R,JANSEN J F A,VAN BOXTEL M P J,et al. Cognitive resilience depends on white matter connectivity:the Maastricht study[J/OL]. Alzheimers Dement,2022:12758[2023-01-03]. https://doi.org/10.1002/alz.12758. [49] NG F C,CHURILOV L,YASSI N,et al. Prevalence and significance of impaired microvascular tissue reperfusion despite macrovascular angiographic reperfusion(No-Reflow)[J/OL]. Neurology,2022,98(8):e790-e801[2023-01-03]. https://doi.org/10.1212/wnl.0000000000013210. [50] QIU B S,ZHAO Z C,WANG N,et al. A systematic observation of vasodynamics from different segments along the cerebral vasculature in the penumbra zone of awake mice following cerebral ischemia and recanalization[J/OL]. J Cereb Blood Flow Metab,2022:271678x221146128. https://doi.org/10.1177/0271678x221146128. |
[1] | 吴雅婷, 魏宸铭, 武剑. 卒中患者血压水平与卒中后认知障碍关系的研究进展[J]. 中国卒中杂志, 2023, 18(01): 68-75. |
[2] | 田雨, 管玲, 王伊龙. 脑小血管病患者排尿功能紊乱与自主神经功能的相关性研究 [J]. 中国卒中杂志, 2023, 18(01): 76-82. |
[3] | 鲁明, 王韵, 米荷音, 郭佳翔, 郭洪亮, 纪蒙, 胡文立. 伴皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病致老年脑叶出血1例报道[J]. 中国卒中杂志, 2023, 18(01): 103-106. |
[4] | 梁潇, 钱海兵. 水通道蛋白4与卒中后认知障碍的关系研究进展[J]. 中国卒中杂志, 2022, 17(12): 1385-1390. |
[5] | 郑占军, 赵性泉. 脑小血管病影像学标志物与自发性高血压脑出血的相关性研究进展[J]. 中国卒中杂志, 2022, 17(12): 1396-1402. |
[6] | 仇鑫, 李子孝. DNA甲基化与脑血管病[J]. 中国卒中杂志, 2022, 17(11): 1159-1161. |
[7] | 王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177. |
[8] | 刘亚杰, 李玉娣, 黎凯锋, 陈哲锋, 凌莉. 基于高通量RNA-Seq技术探讨补阳还五汤治疗小鼠脑梗死的作用机制 [J]. 中国卒中杂志, 2022, 17(11): 1238-1246. |
[9] | 韩广淞, 倪俊. 烟雾病临床分型研究进展[J]. 中国卒中杂志, 2022, 17(10): 1120-1126. |
[10] | 程安琪, 徐蔚海. 青年卒中遗传学研究进展[J]. 中国卒中杂志, 2022, 17(09): 920-924. |
[11] | 龚宇田, 黎洁洁. IL-6和动脉粥样硬化性缺血性卒中的关系研究进展[J]. 中国卒中杂志, 2022, 17(09): 1022-1026. |
[12] | 张亚清, 刘秀梅, 余苹, 王蓬莲. 脑微出血与认知功能障碍的相关性研究[J]. 中国卒中杂志, 2022, 17(07): 748-752. |
[13] | 陈超, 万慧娟, 董文玉, 王圣松, 余苹, 邵晓秋. 脑小血管病总负荷与中老年癫痫患者认知功能的相关性[J]. 中国卒中杂志, 2022, 17(06): 622-627. |
[14] | 马佳丽, 王玉青, 王恺闻, 东晶晶, 李永秋. 脑小血管病总负荷的影响因素探索及临床预测模型建立[J]. 中国卒中杂志, 2022, 17(05): 523-528. |
[15] | 叶益超, 玉石, 佘亚军, 方正, 王毅. 血管性帕金森综合征的研究进展[J]. 中国卒中杂志, 2022, 17(04): 346-350. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||